肌醇在多囊卵巢综合征生殖管理中的证据评价
本文评述肌醇用于多囊卵巢综合征(PCOS)相关不孕的现有证据,指出国际和国内指南均未将其列为一线治疗,无论是单用还是联合促排卵药物。早期研究提示与克罗米芬或促性腺激素联用可能有获益,但与当前首选来曲唑和GnRH拮抗剂方案脱节。IVF中肌醇或可减少促性腺激素用量并改善部分中间/次要结局,但缺乏活产和长期疗效数据。
要点
- 指南不推荐肌醇作为PCOS相关不孕的一线治疗。
- 与克罗米芬或促性腺激素联用的早期证据已过时。
- IVF中肌醇或减少促性腺激素用量,但缺活产数据。
核心结论
- 现有证据不足以支持肌醇常规用于PCOS生育管理,应仅在循证框架下个体化使用。
研究设计与样本
- 本文为评论性文章,批判性评估肌醇用于PCOS生育管理的现有文献。
主要发现
- 国际和国内指南均未认可肌醇作为PCOS相关不孕的一线治疗,无论单用或联合促排卵药物。
- 早期研究提示肌醇与克罗米芬或促性腺激素联用可能有潜在获益,但研究过时或与当前治疗方案脱节。
- IVF中肌醇可能减少促性腺激素需求量并改善部分中间/次要结局,但缺乏活产和长期疗效数据。
临床怎么用
- 不应将肌醇常规纳入PCOS生育方案,仅在循证框架下对个体化病例考虑使用。
局限性
- 支持肌醇疗效的证据有限且不确定,缺乏设计良好、样本量充足的随机对照试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myo-inositol has gained widespread use in the management of infertility associated with polycystic ovary syndrome (PCOS), driven by its proposed role in improving insulin sensitivity and ovarian function. Despite its popularity in clinical practice, the evidence supporting myo-inositol's efficacy in enhancing fertility outcomes remains limited and inconclusive. Current international and national guidelines do not endorse myo-inositol as a first-line treatment for PCOS-related infertility, either as monotherapy or in combination with ovulation induction agents. Even if early studies suggest potential benefits when used alongside clomiphene citrate or gonadotrophins, these findings are often outdated or misaligned with contemporary treatment protocols that favour letrozole and gonadotrophin-releasing hormone antagonist regimens. In the context of IVF, myo-inositol may reduce gonadotrophin requirements and improve some intermediate/secondary outcomes, although data on live births and long-term efficacy are lacking. This commentary critically evaluates the current literature on use of myo-inositol in PCOS fertility care, emphasizing the need for well-designed, adequately powered randomized controlled trials that reflect current clinical standards. Until stronger evidence is available, myo-inositol should not be routinely recommended in fertility protocols for PCOS but reserved for individualized cases within an evidence-based framework.
引用
- Palomba S, Seminara G, Aversa A, et al. Myo-inositol in reproductive management of women with PCOS: holy grail for medical practice or demon for scientific evidence? Reprod Biomed Online. 2025. PMID: 41456539. doi:10.1016/j.rbmo.2025.105269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。